Eduardo Bravo, Citryll CEO
December 9, 2024 02:00 AM EST
Financing
Startups

Dutch biotech nabs €85M to po­si­tion in­flam­ma­to­ry an­ti­body for a phar­ma buy­er

Kyle LaHucik

Senior Reporter

Cit­ryll, a Dutch biotech that has large­ly flown un­der the radar for most of its near­ly 10-year his­to­ry, has patched to­geth­er an €85 mil­lion Se­ries …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Bio­Marin turns to ex-Roche deal­mak­er James Sabry to build ‘next ver­sion’ of 27-year-old com­pa­ny

Pur­due, Sack­lers reach new $7.4B opi­oid set­tle­ment af­ter SCO­TUS re­jec­tion

As an­oth­er Trump term gets un­der­way, phar­ma ad­vi­sors get com­fort­able with un­cer­tain­ty

Chi­na's biotech boom is threat­en­ing US drug­mak­er­s' dom­i­nance

Ab­b­Vie part­ners with Neo­morph in lat­est mol­e­c­u­lar glue deal

sponsored

Fu­el­ing More Break­throughs: Man­u­fac­tur­ing In­no­va­tion to Ex­pand Gene Ther­a­py’s Reach

A service from the Financial Times